CA3117148A1 - Novel uses - Google Patents

Novel uses Download PDF

Info

Publication number
CA3117148A1
CA3117148A1 CA3117148A CA3117148A CA3117148A1 CA 3117148 A1 CA3117148 A1 CA 3117148A1 CA 3117148 A CA3117148 A CA 3117148A CA 3117148 A CA3117148 A CA 3117148A CA 3117148 A1 CA3117148 A1 CA 3117148A1
Authority
CA
Canada
Prior art keywords
pde1 inhibitor
alkyl
formula
methyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3117148A
Other languages
English (en)
French (fr)
Inventor
Robert E. Davis
Kimberly E. Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CA3117148A1 publication Critical patent/CA3117148A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3117148A 2018-10-21 2019-10-21 Novel uses Pending CA3117148A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748517P 2018-10-21 2018-10-21
US62/748,517 2018-10-21
PCT/US2019/057260 WO2020086481A1 (en) 2018-10-21 2019-10-21 Novel uses

Publications (1)

Publication Number Publication Date
CA3117148A1 true CA3117148A1 (en) 2020-04-30

Family

ID=70331921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3117148A Pending CA3117148A1 (en) 2018-10-21 2019-10-21 Novel uses

Country Status (11)

Country Link
US (2) US12194042B2 (enExample)
EP (1) EP3866808A4 (enExample)
JP (1) JP7480135B2 (enExample)
KR (1) KR20210080418A (enExample)
CN (1) CN113194955A (enExample)
AU (1) AU2019364274C1 (enExample)
BR (1) BR112021007571A2 (enExample)
CA (1) CA3117148A1 (enExample)
IL (1) IL282396A (enExample)
MX (1) MX2021004531A (enExample)
WO (1) WO2020086481A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184240A1 (en) * 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
EP4284806A4 (en) * 2021-01-27 2025-02-26 Intra-Cellular Therapies, Inc. Salt crystals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
EP2939676A1 (en) * 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
EP4112053B1 (en) 2016-10-11 2024-02-14 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Treatment of synucleinopathies

Also Published As

Publication number Publication date
CN113194955A (zh) 2021-07-30
JP2022505471A (ja) 2022-01-14
AU2019364274B2 (en) 2024-10-17
US20250090536A1 (en) 2025-03-20
BR112021007571A2 (pt) 2021-07-27
US20210379072A1 (en) 2021-12-09
WO2020086481A1 (en) 2020-04-30
MX2021004531A (es) 2021-09-10
US12194042B2 (en) 2025-01-14
KR20210080418A (ko) 2021-06-30
IL282396A (en) 2021-06-30
EP3866808A4 (en) 2023-04-12
JP7480135B2 (ja) 2024-05-09
AU2019364274C1 (en) 2025-04-10
EP3866808A1 (en) 2021-08-25
AU2019364274A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US20250090536A1 (en) Uses
US9198924B2 (en) Organic compounds
EP3509589B1 (en) Novel uses
JP6696904B2 (ja) 製剤および医薬組成物
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP7749896B2 (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
US20140271890A1 (en) Controlled-release pharmaceutical composition
US20210369715A1 (en) Novel uses
RU2836384C2 (ru) Новые применения
HK40057178A (en) Novel uses
CZ2004739A3 (cs) Použití desoxypeganinu k ošetřování klinické deprese
US20120094985A1 (en) Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
US11628171B2 (en) Method for treating brain or nerve injury
US20230355625A1 (en) Methods of treatment
RS51331B (sr) Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja
HK1257800A1 (en) Therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240919

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240919

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241021

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20241128

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250129

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250425

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250825

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250825

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250825

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260106

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260219

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260617

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260702

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260702